FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384024002> ?p ?o ?g. }

• W4384024002 abstract "PURPOSE Human epidermal growth factor receptor 2 (HER2) expression (protein immunohistochemistry [IHC] or gene amplification [copy-number variation, CNV]) predicts anti-HER2 therapy responsiveness, although recently it was shown that even low HER2-expressing breast cancers benefit from trastuzumab-deruxtecan. Little is known about HER2 transcriptomic (mRNA) expression, and comparisons between genomic, mRNA, and protein HER2 assays. METHODS HER2 status was evaluated using clinical-grade IHC (protein), quantitative reverse transcription polymerase chain reaction (mRNA), and next-generation sequencing (NGS; amplifications). RESULTS Multi-institutional HER2 testing was performed on 5,305 diverse cancers including non–small-cell lung (n = 1,175), breast (n = 1,040), and colon cancers (n = 566; N = 3,926 tested for CNV; N = 1,848, mRNA; N = 2,533, IHC). Overall, 4.1% (161/3,926) had NGS HER2 amplification; 33.3% (615/1,848) had mRNA overexpression; and 9.3% (236/2,533) were IHC-positive. In 723 patients with all three tests (CNV/mRNA/IHC), various amplification/expression patterns occurred: 7.5% (54/723) had all three HER2 tests positive; 62.8% (454/723) had all three tests negative. Discrepant patterns between amplification and overexpression emerged. For instance, 20% (144/723) of patients had mRNA overexpression alone with negative CNV and IHC. A range in values for only mRNA+ cases occurred in different tumor types (eg, 16.9%, breast; 5%, hepatobiliary). There were 53 patients with various tumors from our institution who had all three assays attempted; 22 tested positive for HER2, and seven received anti-HER2 therapy: two patients achieved response: one (esophageal cancer), complete response (≥42 months); one (cholangiocarcinoma), who only had HER2 mRNA positivity (tissue was inadequate for IHC and CNV assessment), partial response (≥24 months) on HER2-based regimens. CONCLUSION We demonstrate variability of HER2 (protein and mRNA) expression and amplification using comprehensive assays (CNV, mRNA, and IHC) among diverse cancers. As HER2-targeted therapy indications expand, the relative importance of these modalities merits further evaluation." @default.
• W4384024002 created "2023-07-13" @default.
• W4384024002 creator A5053481267 @default.
• W4384024002 creator A5062107881 @default.
• W4384024002 creator A5076517380 @default.
• W4384024002 creator A5086626483 @default.
• W4384024002 date "2023-07-01" @default.
• W4384024002 modified "2023-10-17" @default.
• W4384024002 title "Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies" @default.
• W4384024002 cites W1755920412 @default.
• W4384024002 cites W1782943140 @default.
• W4384024002 cites W1964321121 @default.
• W4384024002 cites W1988373577 @default.
• W4384024002 cites W2007256480 @default.
• W4384024002 cites W2028303084 @default.
• W4384024002 cites W2064394610 @default.
• W4384024002 cites W2070727232 @default.
• W4384024002 cites W2097240274 @default.
• W4384024002 cites W2098775844 @default.
• W4384024002 cites W2100439220 @default.
• W4384024002 cites W2101979288 @default.
• W4384024002 cites W2107413762 @default.
• W4384024002 cites W2121467196 @default.
• W4384024002 cites W2136197678 @default.
• W4384024002 cites W2136561378 @default.
• W4384024002 cites W2146384083 @default.
• W4384024002 cites W2149908785 @default.
• W4384024002 cites W2151101674 @default.
• W4384024002 cites W2159967578 @default.
• W4384024002 cites W2165139474 @default.
• W4384024002 cites W2166199281 @default.
• W4384024002 cites W2264000214 @default.
• W4384024002 cites W2318605753 @default.
• W4384024002 cites W2558839641 @default.
• W4384024002 cites W2624590002 @default.
• W4384024002 cites W2806209829 @default.
• W4384024002 cites W2888939561 @default.
• W4384024002 cites W2902218997 @default.
• W4384024002 cites W2938206352 @default.
• W4384024002 cites W2938634307 @default.
• W4384024002 cites W2976352116 @default.
• W4384024002 cites W2982037499 @default.
• W4384024002 cites W2996630100 @default.
• W4384024002 cites W3005642334 @default.
• W4384024002 cites W3030527465 @default.
• W4384024002 cites W3040676308 @default.
• W4384024002 cites W3082044765 @default.
• W4384024002 cites W3089562193 @default.
• W4384024002 cites W3114100356 @default.
• W4384024002 cites W3126309680 @default.
• W4384024002 cites W3158236003 @default.
• W4384024002 cites W3163865650 @default.
• W4384024002 cites W3203792331 @default.
• W4384024002 cites W3216745145 @default.
• W4384024002 cites W4281640394 @default.
• W4384024002 doi "https://doi.org/10.1200/po.22.00604" @default.
• W4384024002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37437231" @default.
• W4384024002 hasPublicationYear "2023" @default.
• W4384024002 type Work @default.
• W4384024002 citedByCount "0" @default.
• W4384024002 crossrefType "journal-article" @default.
• W4384024002 hasAuthorship W4384024002A5053481267 @default.
• W4384024002 hasAuthorship W4384024002A5062107881 @default.
• W4384024002 hasAuthorship W4384024002A5076517380 @default.
• W4384024002 hasAuthorship W4384024002A5086626483 @default.
• W4384024002 hasBestOaLocation W43840240021 @default.
• W4384024002 hasConcept C104317684 @default.
• W4384024002 hasConcept C105580179 @default.
• W4384024002 hasConcept C120821319 @default.
• W4384024002 hasConcept C121608353 @default.
• W4384024002 hasConcept C126322002 @default.
• W4384024002 hasConcept C141231307 @default.
• W4384024002 hasConcept C142724271 @default.
• W4384024002 hasConcept C153911025 @default.
• W4384024002 hasConcept C204232928 @default.
• W4384024002 hasConcept C2779438470 @default.
• W4384024002 hasConcept C2779786085 @default.
• W4384024002 hasConcept C4692481 @default.
• W4384024002 hasConcept C48023723 @default.
• W4384024002 hasConcept C502942594 @default.
• W4384024002 hasConcept C530470458 @default.
• W4384024002 hasConcept C54355233 @default.
• W4384024002 hasConcept C71924100 @default.
• W4384024002 hasConcept C7602840 @default.
• W4384024002 hasConcept C86803240 @default.
• W4384024002 hasConceptScore W4384024002C104317684 @default.
• W4384024002 hasConceptScore W4384024002C105580179 @default.
• W4384024002 hasConceptScore W4384024002C120821319 @default.
• W4384024002 hasConceptScore W4384024002C121608353 @default.
• W4384024002 hasConceptScore W4384024002C126322002 @default.
• W4384024002 hasConceptScore W4384024002C141231307 @default.
• W4384024002 hasConceptScore W4384024002C142724271 @default.
• W4384024002 hasConceptScore W4384024002C153911025 @default.
• W4384024002 hasConceptScore W4384024002C204232928 @default.
• W4384024002 hasConceptScore W4384024002C2779438470 @default.
• W4384024002 hasConceptScore W4384024002C2779786085 @default.
• W4384024002 hasConceptScore W4384024002C4692481 @default.
• W4384024002 hasConceptScore W4384024002C48023723 @default.
• W4384024002 hasConceptScore W4384024002C502942594 @default.
• W4384024002 hasConceptScore W4384024002C530470458 @default.

• next